addition, several million people with diabetes are estimated to be undiagnosed, thus increasing the risk for developing long-term complications, including macrovascular diseases and end-stage renal disease in a fairly significant fraction of the population. Type 1 diabetes, an autoimmune disease that mainly afflicts children, is characterized by the loss of insulin-producing beta cells. Until now, our understanding of this insidious disease relied on classic genetic approaches including genome wide association studies and single nucleotide polymorphisms. Although 40 immune response related genes have been implicated in type 1 diabetes, we are far from understanding how these genes render susceptibility to this complex disorder. 2 Type 2 diabetes is common among people Ͼ45 years of age and characterized by the lack of serum autoantibodies, progressive insulin resistance, and beta cell insufficiency. Despite the differences in the etiology, both type 1 and type 2 diabetes are associated with microvascular complications such as diabetic nephropathy, neuropathy, and retinopathy, as well as macrovascular cardiovascular diseases including atherosclerosis, hypertension, and stroke. Tight glycemic control for 3 to 5 years may prevent cardiovascular disease but not all diabetes-related endpoints, referred to as the hyperglycemic memory 3 or the legacy effect. 4 Although it is unclear how the external cues such as hyperglycemia is perceived as a signal for gene transcription, several intracellular events including generation of oxidative stress and advanced glycation end products, and engagement of the mitogen activated protein kinase pathway have been implicated in metabolic memory ( Figure) . Recent data indicated a role for epigenetic mechanisms in a preclinical model of type 1 diabetes. 5 Although gene-environment interactions have been implicated in the manifestation of type 2 diabetes, compelling evidence for the involvement of epigenetic mechanisms in the initiation and transmission of the metabolic syndrome to the offspring is not robust. 6 However, accumulating evidence 7,8 is consistent with a role for epigenetic mechanisms in the manifestation of hyperglycemia-induced diabetic vascular complications.
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Several in vivo and in vitro models were developed to complement clinical trials of metabolic memory. Although retinal complications were observed a long time ago in diabetic dogs even after switching to normal glucose control, 9 the underlying mechanisms remain poorly understood. A seminal paper more than 2 decades ago described that rats treated with streptozotocin, a nonspecific cytotoxic agent, induced chronic hyperglycemia and increased the expression of fibronectin mRNA in the kidney cortex, which remained elevated for several weeks even after the maintenance of near-normal glucose levels by exogenous insulin administration. 10 To facilitate the investigation of the mechanisms of hyperglycemic memory, these authors developed an in vitro model in which human umbilical vein endothelial cells were exposed to hyperglycemia. Although the expression of both fibronectin and collagen IV was increased in cells cultured under hyperglycemic condition, cells that were switched to normal glucose level continued to display elevated expression of these genes albeit at lower levels than those cultured continuously in high glucose containing media. Although epigenetic mechanisms were postulated in metabolic memory, 10 these possibilities were explored only recently.
Epigenetic mechanisms including DNA methylation and histone modification represent a paradigm shift in our understanding of changes in gene expression under pathological conditions. 11 Hypomethylation of CpG (cytosine-phosphateguanine) sites at the promoter region generally correspond to gene activation. 12 Methylation of CpG dinucleotides at the promoter region interferes with the binding of transcription factors and promotes the binding of methyl-CpG-binding domain proteins, which in turn recruit histone deacetylases, leading to gene repression. Analysis of methylation levels at the promoter of the insulin-sensitizing adiponectin gene in the placenta indicated that they could serve as an epigenetic adapter of glucose levels in utero. 13 Elucidation of methylome landscape will advance our understanding of the regulation genes underpinning the metabolic memory.
Modification of lysine residue in the histone tail by methylation is a remarkably complex process, involving mono-, di, or trimethylation at highly conserved positions, which often clusters within specific regions resulting in the organization of chromosomes into distinct structural and functional domains. 14 Bovine aortic endothelial cells exposed to high glucose upregulated the expression of the NFkB subunit p65 gene, accompanied by monomethylation of histone 3 at lysine 4 (H3K4m1) but not dimethylation (H3K4m2) or trimethylation of histone 3 at lysine 4 (H3K4m3). 15 Hyperglycemia also had other epigenetic effects, including the suppression of diemthylation (H3K9m2) and trimethylation of H3 at lysine 9 (H3K9m3) in this system. Relevance of histone lysine methylation to gene expression under diabetic conditions was indicated by the constitutive dimethylation of H3K9 at 2 candidate genes in peripheral blood monocytes derived from type 1 and type 2 diabetes patients. 16 Persistence of p65 gene activation was associated with recruitment of SET-domain (suppressor of variegation 3-9, enhancer of zeste, trithroax) containing methyl writer, such as Set7. 15 Knockdown of Set7 confirmed the requirement of Set7-mediated histone methylation in the expression of genes implicated in metabolic memory. It is noteworthy that Set7 is also capable of methylating at K142, leading to proteasomal degradation of human DNA methyl transferase 1, 17 which serves as the maintenance methyl transferase crucial for implementing DNA methylation patterns during DNA replication. Transient hyperglycemia enriched the methyl eraser, lysine specific demethylase 1, on the p65 promoter, which is inversely correlated with H3K9 methylation. 15 Lysine specific demethylase 1 can antagonize Set7mediated DNA methyl transferase 1 methylation, leading to fine-tuning of the methylation status of the enzyme crucial for gene regulation. 17 Among the 50 phylogenically conserved SET-domain containing proteins, Set7 is the only enzyme known to generate monomethylation of histone 4 at lysine 20 (H4K20me1) involved in cell proliferation. 17 It remains to be determined whether hyperproliferation observed earlier in hyperglycemia exposed human umbilical vein endothelial cells is also associated with the generation of H4K20me1 mark. 10 A thorough analysis of the contribution of various functions of Set7 to gene regulation is a prerequisite for designing intervention strategies for the treatment of hyperglycemia associated end stage diseases (Figure) .
More recent work takes a closer look at the role of hyperglycemia-induced gene activation via the methyl writer, Set7 in vascular endothelial cells. 7 Exposure to high glucose induced the accumulation of Set7 in the nucleus without altering the overall level of Set7 protein. Inasmuch as Set7 lacks a nuclear localizing signal, 17 mechanisms involved in the nuclear accumulation of Set7 protein remain enigmatic. Whereas Set7 chromatin localization resulted in the upregulation of interleukin-8 gene in a manner dependent on H3K4m1, the expression of HMOX1 was independent of monomethylation of H3K4 in cell lines. 7 The differential dependence of interleukin-8 and HMOX1 genes and on Set7 mediated monomethylation of H3K4 was reproduced in the aortae harvested from type 2 diabetes-prone C57BL/6 mice injected with high glucose. 7 Thus, hyperglycemia appears to activate Set7-mediated gene expression by differential engagement of histone methylation events.
Posttranslational modification of histones by histone acetylases is a well-characterized epigenetic mechanism, which interacts with DNA methylation to influence gene transcription. [11] [12] Exposure to transient high-glucose-induced hyperacetylation of histone H3K9/K14 within the gene promoters and increased the expression of genes implicated in diabetes and vascular complications, including HMOX1, SLC37A11, MMP10, IL8, CCL2, and ICAM1 in human aortic endothelial cells. 18 The retention of hypoacetylated sequences was mapped to methylated CpG sites and H3K9/K14 acetylation is predictive of unmethylated genomic sequences. 18 Recent studies indicated that epigenetic modulation of the genome using a histone deacetyase inhibitor ameliorated type 1 diabetes in a preclinical model, associated with histone H3 hyperacetylation, specific upregulation of IFN-␥, implicated in protection against type 1 diabetes, and its transactivating factor, Tbx21 in NOD mice. 5, 19 It will be interesting to determine whether epigenetic modulation of the genome can attenuate macrovascular complications associated with type 1 and type 2 diabetes in preclinical models. The knowledge gained will bolster our attempts to minimize irreversible consequences of hyperglycemia-induced tissue damage in diabetes.
The fact that not all diabetic patients develop debilitating consequences including end-stage renal disease indicates that an important determinant in the metabolic memory is the genetic background of the responder cell. Although the genetic background has been suspected to contribute to the legacy effect, this viable possibility has not been fully elucidated. Another important piece of the puzzle in understanding the mechanisms of metabolic memory is how the extracellular cues like high levels of glucose are translated into an intracellular signal triggering the nuclear translocation of the methyltransferase Set7 enzyme engendering subsequent events (Figure) . Other epigenetic mechanisms of differential susceptibility of vascular endothelial cells to hyperglycemia may include gene regulation mediated by noncoding RNA and nucleosomal repositioning (Figure) . It appears that in conjunction with undefined genetic factors, epigenetic mechanisms can finetune the regulation of genes involved in diabetic complications. Although mortality due to ischemic cardiac disease is higher among type 1 diabetes patients than in the general population, cardiovascular complications in type 2 diabetes patients receive greater attention. 20 Further work is necessary to fully understand the impact of epigenetic mechanisms on complications of type 1 and type 2 diabetes, which may lead to designing novel treatment strategies for both patient populations.
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Figure.
A model depicting the epigenetic mechanisms involved in metabolic memory. Environmental cues such as hyperglycemia can employ epigenetic mechanisms to alter gene expression, leading to diabetes-associated complications. Exposure to transient hyperglycemia is associated with metabolic changes including the engagement of the mitogen activated protein kinase (MAPK) pathway. The resulting nuclear translocation of Set7 influences gene expression as a consequence of interaction with DNA methyl transferase 1 (DNMT1), which in turn is influenced by lysine specific demethylase 1 (LSD1).
